Barbara A. Binzak Blumenfeld, PhD, is a shareholder at Buchanan Ingersoll & Rooney. She focuses her practice on the regulation of biologic research, and recently spoke with Becker’s Spine Review about where regenerative medicine is headed.
Biologics
Regenerative medicine company CollPlant renewed its exclusive distribution agreement with Arthrex for its soft tissue repair product Vergenix STR.
Regenerative medicine company IMAC Holdings has a new brand ambassador in former Chicago Bears coach Mike Ditka.
Structural allograft may be superior to intervertebral cages in anterior cervical discectomy and fusion, according to a study in Spine.
SpinalCyte was issued new patents in the U.S. and Japan.
Advertisement
The International Society for the Advancement of Spine Surgery issued a new bone grafting policy that includes Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.
Aesculap Biologics achieved 50 percent enrollment in its ongoing phase 3 clinical trial of Novocart 3D, an autologous chondrocyte transplantation system designed to treat articular cartilage defects of the knee.
The global autologous matrix-induced chondrogenesis market is expected to grow at an 8.6 percent compound annual growth rate by 2024, according to a Persistence Market Research report.
Roger Hartl, MD, professor of neurological surgery and director of spine surgery at Weill Cornell Medicine in New York City, as well as director of the Weill Cornell Medicine Center for Comprehensive Spine Care, discusses the key trends in spine…
Medtronic launched Grafton Demineralized Bone Matrix for spine and orthopedic procedures in Japan.